Treatment of Pediatric Status Epilepticus

Pediatric Neurology (Harvey S. Singer, Section Editor)

Opinion statement

Status epilepticus is characterized by a prolonged, self-sustaining seizure or repeated seizures without return to baseline. The clinical manifestations of status epilepticus in children and adults range from overt generalized convulsions to more subtle behavioral manifestations, including unresponsiveness in the setting of the intensive care unit. Status epilepticus is the most common neurologic emergency of childhood. A large proportion of these episodes are the result of a prolonged febrile seizure or an acute symptomatic etiology. Fortunately, status epilepticus occurs without consequence for many children, but for others, it is correlated with long-term neurologic dysfunction or death. Treatment of status epilepticus should commence promptly upon its recognition, using predefined treatment protocols. The goal of treatment is the rapid termination of the seizure, to minimize the acute and chronic effects of this emergency and to allow for the prompt assessment and management of the underlying precipitant. Currently, the drug class of first choice in the in-hospital and out-of-hospital treatment of status epilepticus is the benzodiazepines, which may need to be quickly followed by a next-line agent, as the efficacy of the benzodiazepines is negatively correlated with seizure duration. Traditionally, these next-line agents have included phenobarbital and phenytoin, but emerging evidence supports the use of intravenous formulations of other antiepileptic drugs. If the first two agents fail, high-dose intravenous midazolam or anesthetic therapy should be rapidly initiated. This paper reviews the current treatment options and strategies for pediatric patients with status epilepticus.



Dr. Loddenkemper serves on the Laboratory Accreditation Board for Long-Term (Epilepsy and ICU) Monitoring (ABRET); performs video-EEG long-term monitoring, EEGs, and other electrophysiological studies at Children’s Hospital Boston and bills for these procedures; is funded by an Early Career Physician-Scientist Award by the Milken Family Foundation and American Epilepsy Society, by the Epilepsy Foundation of America, by the Center for Integration of Medicine and Innovative Technology, by the NIH, by the Translational Research Program at Children’s Hospital Boston, by the Program for Patient Safety and Quality at Children’s Hospital Boston, and by a Career Development Fellowship Award from Harvard Medical School and Children’s Hospital Boston; and received investigator-initiated research support from Eisai Inc within the past year.

Dr. Goodkin has served as a consultant to Avanir Pharmaceuticals within the past year. He receives research support from the National Institutes of Health.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Chen JWY, Wasterlain CG. Status epilepticus: pathophysiology and management in adults. Lancet Neurol. 2006;5:246–56.PubMedCrossRefGoogle Scholar
  2. 2.
    DeLorenzo RJ, Hauser WA, Towne AR, et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology. 1996;46:1029–35.PubMedGoogle Scholar
  3. 3.
    Chin RF, Neville BG, Peckham, et al. Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: prospective population-based study. Lancet. 2006;368:222–9.PubMedCrossRefGoogle Scholar
  4. 4.••
    Lewena S, Pennington V, Acworth J, et al: Emergency management of pediatric convulsive status epilepticus: a multicenter study of 542 patients. Pediatr Emerg Care 2009;25:83–7.PubMedCrossRefGoogle Scholar
  5. 5.•
    Kravljanac R, Jovic N, Djuric M, et al.: Outcome of status epilepticus in children treated in the intensive care unit: a study of 302 cases, Epilepsia 2011;52:358–63.PubMedGoogle Scholar
  6. 6.
    Neligan A, Shorvon SD. Prognostic factors, morbidity and mortality in tonic-clonic status epilepticus: a review. Epilepsy Res. 2011;93:1–10.PubMedCrossRefGoogle Scholar
  7. 7.••
    Abend, NS, Gutierrez-Colina AM, Topjian AA, et al.: Nonconvulsive seizures are common in critically ill children. Neurology 2011;76:1071–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Riviello Jr JJ, Ashwal S, Hirtz D, et al. Practice parameter: diagnostic assessment of the child with status epilepticus (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2006;67:1542–50.PubMedCrossRefGoogle Scholar
  9. 9.
    Shneker BF, Fountain NB. Assessment of acute morbidity and mortality in nonconvulsive status epilepticus. Neurology. 2003;61:1066–73.PubMedGoogle Scholar
  10. 10.
    Loddenkemper T, Nichol SM, Allred EN, et al. Fears and promises of comparative effectiveness research. Acta Paediatr. 2010;99:1311–3.PubMedCrossRefGoogle Scholar
  11. 11.
    Shinnar S. Who is at risk for prolonged seizures? J Child Neurol. 2007;22(5 Suppl):14S–20S.PubMedCrossRefGoogle Scholar
  12. 12.
    Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med. 1998;339:792–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Chin RF, Neville BG, Peckham C, et al. Treatment of community-onset, childhood convulsive status epilepticus: a prospective, population-based study. Lancet Neurol. 2008;7:696–703.PubMedCrossRefGoogle Scholar
  14. 14.
    Lambrechtsen FA, Buchhalter JR. Aborted and refractory status epilepticus in children: a comparative analysis. Epilepsia. 2008;49:615–25.PubMedCrossRefGoogle Scholar
  15. 15.
    Lowenstein DH, Bleck T, Macdonald RL. It’s time to revise the definition of status epilepticus. Epilepsia. 1999;40:120–2.PubMedCrossRefGoogle Scholar
  16. 16.
    Mpimbaza A, Ndeezi G, Staedke S, et al. Comparison of buccal midazolam with rectal diazepam in the treatment of prolonged seizures in Ugandan children: a randomized clinical trial. Pediatrics. 2008;121:e58–64.PubMedCrossRefGoogle Scholar
  17. 17.•
    Holsti M, Dudley N, Schunk J, et al.: Intranasal midazolam vs rectal diazepam for the home treatment of acute seizures in pediatric patients with epilepsy. Arch Ped Adolesc Med 2010;164:747–53.CrossRefGoogle Scholar
  18. 18.
    Alldredge BK, Gelb AM, Isaacs SM, et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med. 2001;345:631–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Kapur J. Prehospital treatment of status epilepticus with benzodiazepines is effective and safe. Epilepsy Curr. 2002;2:121–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Aranda A, Foucart G, Ducasse JL, et al. Generalized convulsive status epilepticus management in adults: a cohort study with evaluation of professional practice. Epilepsia. 2010;51:2159–67.PubMedCrossRefGoogle Scholar
  21. 21.
    Chin RF, Verhulst L, Neville BG, et al. Inappropriate emergency management of status epilepticus in children contributes to need for intensive care. J Neurol Neurosurg Psych. 2004;75:1584–8.CrossRefGoogle Scholar
  22. 22.
    Goodkin HP, Kapur J. The impact of diazepam’s discovery on the treatment and understanding of status epilepticus. Epilepsia. 2009;50:2011–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Appleton R, Macleod S, Martland T. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. Cochrane Database Syst Rev. 2008;16:CD001905.Google Scholar
  24. 24.
    McMullan J, Sasson C, Pancioli A, et al. Midazolam versus diazepam for the treatment of status epilepticus in children and young adults: a meta-analysis. Acad Emerg Med. 2010;17:575–82.PubMedCrossRefGoogle Scholar
  25. 25.
    Zaw W, Knoppert DC, da Silva O. Flumazenil’s reversal of myoclonic-like movements associated with midazolam in term newborns. Pharmacotherapy. 2001;21:642–6.PubMedCrossRefGoogle Scholar
  26. 26.•
    Sreenath TG, Gupta P, Sharma KK, et al.: Lorazepam versus diazepam-phenytoin combination in the treatment of convulsive status epilepticus in children: a randomized controlled trial. Eur J Paediatr Neurol 2010;14:162–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Appleton RE, Gill A. Adverse events associated with intravenous phenytoin in children: a prospective study. Seizure. 2003;12:369–72.PubMedCrossRefGoogle Scholar
  28. 28.
    Wilmshurst JM, van der Walt JS, Ackermann SA, et al. Rescue therapy with high-dose oral phenobarbitone loading for refractory status epilepticus. J Paediatr Child Health. 2010;46:17–22.PubMedCrossRefGoogle Scholar
  29. 29.
    Mehta V, Singhi P, Singhi S. Intravenous sodium valproate versus diazepam infusion for the control of refractory status epilepticus in children: a randomized controlled trial. J Child Neurol. 2007;22:1191–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Uberall MA, Trollmann R, Wunsiedler U, et al. Intravenous valproate in pediatric epilepsy patients with refractory status epilepticus. Neurology. 2000;13:2188–9.Google Scholar
  31. 31.
    Reiter PD, Huff AD, Knupp KG, et al. Intravenous levetiracetam in the management of acute seizures in children. Pediatr Neurol. 2010;43:117–21.PubMedCrossRefGoogle Scholar
  32. 32.
    Barrueto Jr F, Williams K, Howland MA, et al. A case of levetiracetam (Keppra) poisoning with clinical and toxicokinetic data. J Toxicol Clin Toxicol. 2002;40:881–4.PubMedCrossRefGoogle Scholar
  33. 33.
    Shiloh-Malawsky Y, Fan Z, Greenwood R, et al. Successful treatment of childhood prolonged refractory status epilepticus with lacosamide. Seizure. 2011;20:586–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Guilhoto LM, Loddenkemper T, Gooty VD, et al. Experience with lacosamide in a series of children with drug-resistant focal epilepsy. Pediatr Neurol. 2011;44:414–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Riviello Jr JJ. Seizures in the context of acute illness. Curr Opin Pediatr. 2009;21:731–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Rossetti AO, Milligan TA, Vulliemoz S, et al. A randomized trial for the treatment of refractory status epilepticus. Neurocrit Care. 2011;14:4–10.PubMedCrossRefGoogle Scholar
  37. 37.
    Sahin M, Menache CC, Holmes GL, et al. Prolonged treatment for acute symptomatic refractory status epilepticus: outcome in children. Neurology. 2003;61:398–401.PubMedGoogle Scholar
  38. 38.
    Hayashi K, Osawa M, Aihara M, et al. Efficacy of intravenous midazolam for status epilepticus in childhood. Pediatr Neurol. 2007;36:366–72.PubMedCrossRefGoogle Scholar
  39. 39.
    Kim SJ, Lee DY, Kim JS. Neurologic outcomes of pediatric epileptic patients with pentobarbital coma. Pediatr Neurol. 2001;25:217–20.PubMedCrossRefGoogle Scholar
  40. 40.
    Iyer VN, Hoel R, Rabinstein AA. Propofol infusion syndrome in patients with refractory status epilepticus: an 11-year clinical experience. Crit Care Med. 2009;37:3024–30.PubMedCrossRefGoogle Scholar
  41. 41.
    da Silva SS, Wong R, Coquillon P, et al. Partial-exchange blood transfusion: an effective method for preventing mortality in a child with propofol infusion syndrome. Pediatrics. 2010;125:e1493–9.CrossRefGoogle Scholar
  42. 42.
    Hsieh CY, Sung PS, Tsai JJ, et al. Terminating prolonged refractory status epilepticus using ketamine. Clin Neuropharmacol. 2010;33:165–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Mewasingh LD, Sekhara T, Aeby A, et al. Oral ketamine in paediatric non-convulsive status epilepticus. Seizure. 2003;12:483–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Akyildiz BN, Kumandas S. Treatment of pediatric refractory status epilepticus with topiramate. Childs Nerv Syst. 2011;27:1425–30.PubMedCrossRefGoogle Scholar
  45. 45.
    Novy J, Rossetti AO. Oral pregabalin as an add-on treatment for status epilepticus. Epilepsia. 2010;51:2207–10.PubMedCrossRefGoogle Scholar
  46. 46.
    Vendrame M, Loddenkemper T. Surgical treatment of refractory status epilepticus in children: candidate selection and outcome. Semin Pediatr Neurol. 2010;17:182–9.PubMedCrossRefGoogle Scholar
  47. 47.
    De Herdt V, Waterschoot L, Vonck K, et al. Vagus nerve stimulation for refractory status epilepticus. Eur J Paediatr Neurol. 2009;13:286–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Corry JJ, Dhar R, Murphy T, et al. Hypothermia for refractory status epilepticus. Neurocrit Care. 2008;9:189–97.PubMedCrossRefGoogle Scholar
  49. 49.
    Shin HW, O’Donovan CA, Boggs JG, et al. Successful ECT treatment for medically refractory nonconvulsive status epilepticus in pediatric patient. Seizure. 2011;20:433–6.PubMedCrossRefGoogle Scholar
  50. 50.
    Kamel H, Cornes SB, Hegde M, et al. Electroconvulsive therapy for refractory status epilepticus: a case series. Neurocrit Care. 2010;12:204–10.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Harvard Medical School, Division of Epilepsy and Clinical Neurophysiology, Fegan 9Children’s Hospital BostonBostonUSA
  2. 2.Departments of Neurology and PediatricsUniversity of Virginia Health SystemsCharlottesvilleUSA

Personalised recommendations